Documentos clave

Ver Toda la documentación

Saltar a

1420006

USP

Levodopa Related Compound B

Name: Levodopa Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

DL-3-O-Methyldopa, 3-Methoxytyrosine

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Tamaño de envase	SKU	Disponibilidad	Precio

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₀H₁₃NO₄

Número CAS:

7636-26-2

Peso molecular:

211.21

MDL number:

MFCD00063077

UNSPSC Code:

41116107

NACRES:

NA.24

En este momento no podemos mostrarle ni los precios ni la disponibilidad

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

grade

pharmaceutical primary standard

agency

USP

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(Cc1cc(c(cc1)O)OC)C(=O)O

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

Descripción

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:

Carbidopa and Levodopa Orally Disintegrating Tablets
Levodopa
Carbidopa and Levodopa Tablets
Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo	PHR2096	PHR2095	1361010
USP 1420006 Levodopa Related Compound B	Supelco PHR2096 Levodopa Related Compound B	Supelco PHR2095 Levodopa Related Compound A	USP 1361010 Levadopa Related Compound A
grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard	grade certified reference material, pharmaceutical secondary standard	grade pharmaceutical primary standard
manufacturer/tradename USP	manufacturer/tradename -	manufacturer/tradename -	manufacturer/tradename USP
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical small molecule	application(s) pharmaceutical small molecule	application(s) pharmaceutical (small molecule)
format neat	format neat	format -	format neat
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. −20°C
API family levodopa	API family levodopa	API family levodopa	API family levadopa

Still not finding the right product?

Explore all of our products under Levodopa Related Compound B

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.

Yoritaka Onzawa et al.

Biological & pharmaceutical bulletin, 35(8), 1244-1248 (2012-08-07)

It has been well known that 3-O-methyldopa (3-OMD) is a metabolite of L-3,4-dihydroxyphenylalanine (L-DOPA) formed by catechol O-methyltransferase (COMT), and 3-OMD blood level often reaches higher than physiological level in Parkinson's disease (PD) patients receiving long term L-DOPA therapy. However

Clinical (video) findings and cerebrospinal fluid neurotransmitters in 2 children with severe chronic bilirubin encephalopathy, including a former preterm infant without marked hyperbilirubinemia VIDEO.

Stephanie L Merhar et al.

Pediatrics, 116(5), 1226-1230 (2005-11-03)

Chronic bilirubin encephalopathy, characterized clinically by extrapyramidal movement abnormalities, vertical gaze abnormalities, and hearing loss, results from neuronal injury after marked hyperbilirubinemia in term and preterm infants. In premature infants, bilirubin staining of specific brain structures has been described at

Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Thomas Müller et al.

Naunyn-Schmiedeberg's archives of pharmacology, 383(6), 627-633 (2011-05-03)

Elevation of plasma total homocysteine concentrations were observed in levodopa/dopa decarboxylase inhibitor (DDI)-treated patients with Parkinson's disease (PD). Degradation of levodopa to 3-O-methyldopa via the enzyme catechol-O-methyltransferase (COMT) is a methyl group demanding reaction. It generates homocysteine from the methyl

Ver todos los artículos relacionados

Número de artículo de comercio global

SKU	GTIN
1420006-50MG	04061833860533

Questions

Reviews

No rating value